GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Chemcrux Enterprises Ltd

Chemcrux Enterprises Q2 FY27 Standalone Profit Rises to INR 162.42 Lacs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 02 Nov 2026, 02:36 PM IST  ·  BSE ID: 2bcac3c5-34e9-4475-a802-0a1e5509072c
View Original BSE Filing (PDF)
💡
In Simple Terms
Chemcrux Enterprises announced its Q2 FY27 financial results, showing significant profit and revenue growth compared to last year.
🤖 AI Summary
  • Chemcrux Enterprises' standalone net profit for Q2 FY27 increased to INR 162.42 Lacs, a 103.15% YoY growth.
  • Quarterly revenue from operations stood at INR 2,384.30 Lacs for Q2 FY27, up 28.52% from Q2 FY26.
  • Half-year standalone net profit for FY27 reached INR 299.85 Lacs, marking a 116.66% YoY rise.
  • Half-year revenue from operations for FY27 was INR 4,578.11 Lacs, a 29.69% increase YoY.
  • The Board of Directors approved both standalone and consolidated unaudited financial results for the period.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
2,384.30 INR Lacs
28.52%
Net Profit for the period (Q2 FY27)
162.42 INR Lacs
103.15%
Total Income (Half Year FY27)
4,639.67 INR Lacs
26.40%
Net Profit for the period (Half Year FY27)
299.85 INR Lacs
116.66%
Basic EPS (Q2 FY27)
1.10 Rs.
103.70%
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations to INR 2,384.30 Lacs for Q2 FY27 indicates growth in the company's core business of manufacturing and processing bulk drug intermediates.
💰
Financial Impact
Net profit for Q2 FY27 grew to INR 162.42 Lacs, alongside a half-year net profit of INR 299.85 Lacs, which improves the company's earnings profile.
⚙️
Operational Impact
No specific operational changes are directly indicated in the financial results beyond standard business operations and accounting for employee stock options.
⚠️
Risk Impact
The note regarding Employee Stock Options pending final valuation by an Independent Registered Valuer presents a minor accounting risk, though management expects any adjustments to be non-material.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's profitability and revenue growth directly influence the underlying value of their holdings. The earnings per share (Basic and Diluted) for Q2 FY27 is Rs. 1.10.
🔍
Management Signal
Management's approval of the unaudited financial results and disclosure of ESOP details indicates adherence to regulatory compliance and transparent reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check revenue and profit continuity.
Final valuation report for ESOPs — monitor potential accounting adjustments.
Any updates on outstanding dues of micro enterprises and small enterprises.
LOW RISK Minor accounting note on ESOP valuation pending, with management expecting non-material impact.
💡 Investor Takeaway
Chemcrux Enterprises reported Q2 FY27 standalone net profit of INR 162.42 Lacs, marking a 103.15% increase from INR 79.95 Lacs in Q2 FY26. Revenue from operations for the quarter also increased by 28.52% to INR 2,384.30 Lacs compared to INR 1,855.31 Lacs in Q2 FY26.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 standalone net profit of INR 162.42 Lacs shows a 103.15% increase compared to INR 79.95 Lacs in Q2 FY26.
  • Revenue from operations for Q2 FY27 grew by 28.52% YoY to INR 2,384.30 Lacs from INR 1,855.31 Lacs in Q2 FY26.

⚠️ Concerns

  • Trade payables for micro and small enterprises increased to INR 559.92 Lacs as of September 30, 2026, from INR 85.10 Lacs as of March 31, 2026.
  • Other non-current assets and Other current assets decreased to 0 and INR 97.62 Lacs respectively from prior periods.
📅 Company Track Record
Chemcrux Enterprises' Q1 FY27 standalone profit increased by 135.12% YoY to INR 137.43 Lacs. This current Q2 FY27 performance follows a trend of strong quarterly profit growth, with half-year results showing a 116.66% increase.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Chemcrux Enterprises' standalone net profit for Q2 FY27?
Chemcrux Enterprises reported a standalone net profit of INR 162.42 Lacs for the quarter ended 30 September 2026 (Q2 FY27).
How much was Chemcrux Enterprises' revenue from operations in Q2 FY27?
Revenue from operations for Chemcrux Enterprises in Q2 FY27 was INR 2,384.30 Lacs, an increase from INR 1,855.31 Lacs in Q2 FY26.
What is the half-year net profit for Chemcrux Enterprises for FY27?
The standalone net profit for the half year ended 30 September 2026 (FY27) was INR 299.85 Lacs, up from INR 138.39 Lacs in the previous half year.
What was the Basic Earnings Per Share (EPS) for Chemcrux Enterprises in Q2 FY27?
The Basic Earnings Per Share (EPS) for Chemcrux Enterprises in Q2 FY27 was Rs. 1.10.
Were Employee Stock Options granted by Chemcrux Enterprises in FY27?
Yes, on 15 May 2026, Chemcrux Enterprises granted 1,07,700 Employee Stock Options to eligible employees under the ESOP 2025 Scheme at an exercise price of Rs. 210 per share.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.